Friday-Saturday, April 19-20,2024
MORE INFORMATION AND REGISTER >>
Given the increasing discovery of oncogenic-driven tumors, targeted treatments with novel agents have transformed the outcomes in these patients. Clinical decision making and management therefore have become more complex. There is a need to provide an opportunity for medical oncologists, radiation oncologists, pathologists, allied health professionals, oncology nurses and pharmacists to engage in thoughtful discussions with experts in these fields. In addition, there is emerging data about the biology of these malignancies impacting optimal management of patients with these disorders.
This one-and-a-half-day symposium has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of solid tumors — including lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas and brain tumors — by novel targeted agents and treatment combinations. Updates on evolving molecular-based system therapies will be profiled and discussed.
Upon completion of this symposium, participants should be better able to:
- Summarize the evolving therapeutic strategies in the treatment of solid tumor malignancies.
- Provide an update of new molecular and targeted treatments being developed for these diseases.
- Discuss the rationale for new targeted diagnostic and therapeutic strategies for lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas and brain tumors.
- Review the role and timing of diagnostic tests, molecular profiling and potential combinations of targeted therapy treatment options.